Compare Invesco S&P 500 Momentum ETF (SPMO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Momentum ETF vs TG Therapeutics Inc — how do they compare? Invesco S&P 500 Momentum ETF trades at $151.15, while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SPMO | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $161.66 | $59.06 |
52-Week Low | $107.84 | $26.94 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPMO, trading at $151.89 with a 2.15% daily gain, shows strong momentum-driven performance, supported by a bullish technical signal from moving averages and positive media coverage highlighting its 26% returns year-to-date. The ETF's concentrated, tech-heavy portfolio leverages AI growth trends, though key financial ratios like P/E and P/S are not disclosed in the provided data. A dividend of $0.25 is scheduled for June 2026, adding income potential for investors.
The outlook for SPMO remains favorable due to sustained momentum factor strength and institutional interest, but risks include high volatility from sector concentration and potential downturns during market rotations. Investors should weigh the ETF's cost efficiency and historical outperformance against its exposure to tech sector swings.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
